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For more than 100 years, antivenoms have been produced by traditional methods of immunization of 34 
large mammals with mixtures of snake venoms (WHO, 2010; Gutiérrez et al., 2011). With the 35 
introduction of proteomic and transcriptomic tools in the molecular analysis of both venoms 36 
(venomics) (Calvete, 2014) and antivenoms (antivenomics) (Calvete, 2011, Calvete et al., 2014), in 37 
combination with the toxicological assessment of venoms, a more in-depth understanding of venom 38 
composition and antivenom efficacy is being built. As retrieved from current public databases on 39 
Elapidae, values for Median Lethal Dose (LD50) are known for 203 toxins, belonging to seven protein 40 
sub-families, originating from 40 species (Fig. 1). Furthermore, the number of elapids for which 41 
venom-wide proteomics or transcriptomics studies have been reported has now reached 49 out of 42 
355 described species (our unpublished data; http://www.reptile-database.org). Information is now 43 
available for a considerable number of species of high medical relevance. 44 
Taken together, these insights, and new information being published, may provide the 45 
grounds for a knowledge-based design of future antivenoms, based on the identification of the 46 
toxicologically most relevant toxins in venoms. Scientific efforts have so far mainly been centered 47 
around molecular targeting of relevant snake toxins by using synthetic inhibitors (de Oliveira et al., 48 
2003, Howes et al., 2007), nanobodies (Richard et al., 2013), or antibody fragments (Kulkeaw et al., 49 
2009, Tamarozzi et al., 2006). However, a limitation for introducing novel antitoxins or inhibitors is 50 
that they usually only target one or few individual toxins, and not the whole venom, which typically 51 
contains many toxins belonging to various protein families (Calvete, 2011). For many snake venoms, 52 
this challenge could be overcome if a complete overview of the effect of each toxin in the venom 53 
were at hand; this would allow a distinction between toxins that are essential to neutralize in 54 
envenoming cases, and toxins/proteins that are not pathophysiologically important. This could in the 55 
future enable researchers to develop antitoxins against the medically relevant toxins and use 56 
mixtures of these antitoxins as a replacement, or reinforcement, of antivenoms (Roncolato et al., 57 
2013), potentially providing better efficacy and safety, and lower cost of treatment. We argue that 58 
despite the wealth of efforts within characterization of snake venoms, a lack of a systematic approach 59 
for evaluating the importance of individual toxins within whole venom still exists. Furthermore, no 60 
simple tool has been presented for evaluating whether a given toxin in a snake venom is of sufficient 61 
medical relevance to justify an antitoxin discovery program against it. Without such a tool, modern 62 
antivenom research based on molecular biology, medicinal chemistry, and biotechnology risks 63 
becoming unfocused in the jungle of snake venom and antivenom data. 64 
Primarily two properties of toxins are relevant when evaluating their potential medical 65 
impact: 1) Intrinsic toxicity, and 2) abundance in venom. A systematic method for evaluating the 66 
relevance for acute toxicity, i.e. lethality, of each toxin in whole venom, taking both toxicity and 67 
abundance into account, was recently presented (Laustsen et al., 2015a). This method is based on a 68 
Toxicity Score, which is calculated for either a toxin or whole venom itself by dividing the relative 69 
toxin abundance in the venom (in percentage) by the LD50 value for the toxin in mice. If the 70 
confidence intervals are known for both the abundance and LD50, a confidence interval for the 71 
Toxicity Score can be easily calculated. This parameter was initially proposed for ranking the medical 72 
importance of toxins in the venom of the black mamba, Dendroaspis polylepis (Lautstsen et al., 73 
2015a). Further studies on Naja kaouthia and Aipysurus laevis venoms strongly suggest that Toxicity 74 
Score is likely to be a better parameter to determine the medical relevance of a toxin than LD50 75 
estimation alone, and may be used for assessing the relative importance of toxins in whole venom 76 
(Laustsen et al., 2015b, Laustsen et al., 2015c). The Toxicity Score can be used to quickly assess 77 
whether, for example, a toxin of high abundance and moderate toxicity is of higher importance than a 78 
very potent toxin of low abundance. This approach provides an easy, systematic method for 79 
identifying the key toxins that antivenom development should focus on. Table 1 presents an example 80 
of estimation of the Toxicity Score. 81 
When the Toxicity Score is used to select the relevant toxins, which should be neutralized by 82 
an antivenom or an inhibitor, a decision has to be made to define a threshold value for relevance. For 83 
snakes that are able to inject large amounts of venom into their prey or predators, even toxins with a 84 
low Toxicity Score may become important. Therefore, the minimum cut-off value for the Toxicity 85 
Score has to be analyzed on a case-by-case basis and has to take into account the total amount of 86 
venom that the specific snake is able to inject in a bite. Table 2 illustrates an example on how to 87 
determine the relevant toxins in a venom on the basis of a cut-off value for the Toxicity Score of 5. 88 
Using reported venom yields from milking of snakes (e.g. the values reported on 89 
http://snakedatabase.org/pages/LD50.php) provides a basis for the worst-case upper limit of venom 90 
that may be injected in a bite from different snake species. For example, from our previous work on 91 
the venom of Naja kaouthia (Laustsen et al., 2015b), reported in this database to deliver up to 742 mg 92 
of venom, a cut-off value of the Toxicity Score of 5 would select a group of 5 neurotoxins of the three-93 
finger toxin family and one PLA2 among a total of 28 fractions as the most relevant targets to 94 
neutralize. Fractions with a Toxicity Score below this value would have less than 37 LD50s for an 95 
envenoming with the maximum yield of 742 mg, and are thus likely not to play a significant role in 96 
overall venom toxicity. 97 
The issue of potential synergism between venom components has to be taken into 98 
consideration when selecting key toxins to focus antivenom development efforts on. Using the 99 
Toxicity Score allows for the identification of venoms where toxins display synergistic effects. As 100 
shown in the cases of D. polylepis (Laustsen et al., 2015a) and A. laevis (Laustsen et al., 2015c) 101 
venoms, the Toxicity Score of the whole venom is higher than the sum of Toxicity Scores of individual 102 
toxins, thus indicating the presence of synergism. In these cases it is relevant to further investigate 103 
the synergistic effects by assessing the toxicities of pairs of toxins in order to identify proteins of low 104 
Toxicity Score, but which exert synergistic effects. An example of such an approach is given by 105 
Strydom (1976) for toxins from D. polylepis venom. Despite their low intrinsic toxicity, synergistically 106 
acting toxins would also be good candidates to include in an antivenom development program.  107 
The Toxicity Score can be readily applied to the study of elapid snake venoms because: (a) 108 
the main toxic activity of these venoms is neuromuscular paralysis leading to respiratory arrest and 109 
death, thus making the assessment of lethality a clinically-relevant parameter; (b) the solvents used in 110 
many separation methods (such as the commonly used reverse-phase HPLC) do not generally 111 
denature the most relevant elapid venom toxins, such as three-finger toxins, dendrotoxins, and 112 
phospholipases A2 (PLA2) (Fry et al., 2015); and (c) the mouse model used in the determination of LD50 113 
is generally relevant to the human situation, as the physiological mechanisms involved in 114 
neuromuscular transmission in mice and humans are similar.  115 
The use of this parameter in viperid snake venoms might be more complicated, for the 116 
following reasons: (a) Although lethality is the most serious complication of viperid envenomings, 117 
other aspects also have high medical relevance, such as local tissue damage, i.e. necrosis and 118 
hemorrhage, and systemic effects such as coagulopathy and systemic hemorrhage (Warrell, 2010). (b) 119 
The solvents used in reverse phase-HPLC, especially acetonitrile, denature relevant toxins in viperid 120 
venoms, particularly zinc-dependent metalloproteinases (SVMPs), thus affecting their toxicity. It is 121 
likely, nevertheless, that these two hurdles might be overcome in the future, with the development of 122 
non-denaturing separation methods of high resolution. At present, using the Toxicity Score is 123 
therefore only feasible for focusing development efforts on elapid antivenoms, where the toxins do 124 
not loose activity in the purification process. An exception is the case of some Australian elapid 125 
venoms containing potent procoagulant serine proteinases playing a significant role in toxicity (Kini, 126 
2005), which could be affected by chromatographic solvents; however, the key toxins in the vast 127 
majority of elapid venoms can withstand solvents used in reverse-phase HPLC.  128 
The Toxicity Score has been employed for directing drug discovery efforts against α-129 
cobratoxin, which was shown to have the highest relevance in Naja kaouthia venom (Laustsen et al., 130 
2015b), using phage display screening (Laustsen et al., 2015d). In this example, the Toxicity Score 131 
predicts that blocking the action of D-cobratoxin will abrogate the overall toxicity of the venom. In 132 
conclusion, when working with elapid venoms, using the Toxicity Score may thus provide a clearer 133 
path for determining the medical importance of different toxins in whole venom for the development 134 
of toxin inhibitors and the improvement of antivenoms.  135 
 136 
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Table 1: Example of how Toxicity Scores are calculated for three toxins and whole venom. 192 
 193 
 Abundance (%) LD50 (mg/kg) Toxicity Score* 
Toxin 1 10 0.1 100 
Toxin 2 20 2 10 
Toxin 3 50 1 50 
Whole venom 100 0.25 400 
 194 
*                                  195 
 196 
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 214 
Table 2: Example of how Toxicity Scores may help distinguish between medically relevant and non-215 
relevant toxins/proteins, when selecting targets for focused antivenom development. 216 
 
Abundance (%) LD50 (mg/kg) Toxicity Score Medically relevant 
Whole venom 100 0.25 400 
 
Toxin A 10 0.05 200 Yes 
Toxin B 20 0.2 100 Yes 
Toxin C 50 1 50 Yes 
Toxin D 10 10 1 No 
Toxin E 10 10 
1 
No 
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 234 
Figure legend 235 
Figure 1: Overview of numbers of elapid snake venom toxins for which toxicity, as judged by 236 
estimation of Median Lethal Dose (LD50), has been assessed. Snake genera are highlighted in A by 237 
color codes.  238 
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